Show simple item record  

dc.contributor.authorCameron, Michael Patrick
dc.contributor.authorNewman, Peter A.
dc.contributor.authorRoungprakhon, Surachet
dc.contributor.authorScarpa, Riccardo
dc.identifier.citationCameron, M. P., Newman, P. A., Roungprakhon, S., & Scarpa, R. (2013). The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine, 31(36), 3712-3717.en_NZ
dc.description.abstractThis paper estimates the marginal willingness-to-pay for attributes of a hypothetical HIV vaccine using discrete choice modeling. We use primary data from 326 respondents from Bangkok and Chiang Mai, Thailand, in 2008–2009, selected using purposive, venue-based sampling across two strata. Participants completed a structured questionnaire and full rank discrete choice modeling task administered using computer-assisted personal interviewing. The choice experiment was used to rank eight hypothetical HIV vaccine scenarios, with each scenario comprising seven attributes (including cost) each of which had two levels. The data were analyzed in two alternative specifications: (1) best-worst; and (2) full-rank, using logit likelihood functions estimated with custom routines in Gauss matrix programming language. In the full-rank specification, all vaccine attributes are significant predictors of probability of vaccine choice. The biomedical attributes of the hypothetical HIV vaccine (efficacy, absence of VISP, absence of side effects, and duration of effect) are the most important attributes for HIV vaccine choice. On average respondents are more than twice as likely to accept a vaccine with 99% efficacy, than a vaccine with 50% efficacy. This translates to a willingness to pay US$383 more for a high efficacy vaccine compared with the low efficacy vaccine. Knowledge of the relative importance of determinants of HIV vaccine acceptability is important to ensure the success of future vaccination programs. Future acceptability studies of hypothetical HIV vaccines should use more finely grained biomedical attributes, and could also improve the external validity of results by including more levels of the cost attribute.en_NZ
dc.subjectHIV vaccineen_NZ
dc.subjectconjoint analysisen_NZ
dc.subjectdiscrete choiceen_NZ
dc.titleThe marginal willingness-to-pay for attributes of a hypothetical HIV vaccineen_NZ
dc.typeJournal Articleen_NZ

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record